NO984627L - Implanterbare, agarose-kollagenperler inneholdende celler som produserer et diffuserbart biologisk produkt og anvendelser derav - Google Patents

Implanterbare, agarose-kollagenperler inneholdende celler som produserer et diffuserbart biologisk produkt og anvendelser derav

Info

Publication number
NO984627L
NO984627L NO984627A NO984627A NO984627L NO 984627 L NO984627 L NO 984627L NO 984627 A NO984627 A NO 984627A NO 984627 A NO984627 A NO 984627A NO 984627 L NO984627 L NO 984627L
Authority
NO
Norway
Prior art keywords
agarose
biological product
implantable
produce
containing cells
Prior art date
Application number
NO984627A
Other languages
English (en)
Other versions
NO984627D0 (no
NO320334B1 (no
Inventor
Kanti Jain
Albert L Rubin
Shirin Asina
Barry Smith
Kurt Stenzel
Original Assignee
Rogosin Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/745,063 external-priority patent/US5888497A/en
Application filed by Rogosin Inst filed Critical Rogosin Inst
Publication of NO984627D0 publication Critical patent/NO984627D0/no
Publication of NO984627L publication Critical patent/NO984627L/no
Publication of NO320334B1 publication Critical patent/NO320334B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
NO19984627A 1996-04-03 1998-10-02 Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller. NO320334B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62559596A 1996-04-03 1996-04-03
US08/745,063 US5888497A (en) 1996-04-03 1996-11-07 Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
PCT/US1997/004548 WO1997036495A1 (en) 1996-04-03 1997-03-21 Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof

Publications (3)

Publication Number Publication Date
NO984627D0 NO984627D0 (no) 1998-10-02
NO984627L true NO984627L (no) 1998-11-30
NO320334B1 NO320334B1 (no) 2005-11-21

Family

ID=27089961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984627A NO320334B1 (no) 1996-04-03 1998-10-02 Materialblanding av fast agarose-overtrukket agaroseinneholdende eller agarose-kollagenperle inneholdende celler som produserer et diffunderbart biologisk produkt, anvendelser derav, fremgangsmater for fremstilling derav, kondisjonert medium fremstilt ved hjelp av materialblandingen, samt fremgangsmate for a bestemme om en materialblanding er anvendelig i a undertrykke proliferasjon av cancerceller.

Country Status (15)

Country Link
EP (2) EP1382346B1 (no)
JP (2) JP3765039B2 (no)
CN (2) CN1119080C (no)
AT (2) ATE250858T1 (no)
AU (1) AU722109C (no)
CA (1) CA2250880C (no)
DE (2) DE69725317T2 (no)
DK (2) DK0914043T3 (no)
ES (2) ES2206696T3 (no)
FI (1) FI120332B (no)
IL (1) IL126442A0 (no)
NO (1) NO320334B1 (no)
NZ (2) NZ331960A (no)
PT (1) PT914043E (no)
WO (1) WO1997036495A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US6303151B1 (en) * 1996-04-03 2001-10-16 The Rogosin Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US7297331B2 (en) 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
NO983911D0 (no) 1998-08-26 1998-08-26 Norsk Hydro As Alginatkapsler til bruk ved behandling av hjernesvulst
AU2003264652B2 (en) * 1998-11-09 2006-09-14 The Rogosin Institute Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
US9308252B2 (en) 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8802113B2 (en) 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
US9283266B2 (en) 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
RU2591518C2 (ru) * 2012-01-31 2016-07-20 Де Рогозин Инститьют Инк. Усовершенствованный способ получения макрогранул
WO2019152767A1 (en) 2018-02-02 2019-08-08 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE441009B (sv) * 1982-03-08 1985-09-02 Kjell Nilsson Sett att immobilisera levande biomaterial i perlformiga polymerer
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
CA1196862A (en) * 1983-06-01 1985-11-19 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4663286A (en) * 1984-02-13 1987-05-05 Damon Biotech, Inc. Encapsulation of materials
SE8604684L (sv) * 1986-11-03 1988-05-04 Excorim Kommanditbolag Sett att belegga fasta partiklar med en hydrofil gel samt genom settet belagda partiklar
JP2691557B2 (ja) * 1988-04-15 1997-12-17 興研株式会社 人の悪性腫瘍細胞増殖抑制剤
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
AU681240C (en) * 1994-01-13 2006-12-07 Rogosin Institute, The Macroencapsulated secretory cells
US5651980A (en) * 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles

Also Published As

Publication number Publication date
JP2005104987A (ja) 2005-04-21
CA2250880A1 (en) 1997-10-09
ATE250858T1 (de) 2003-10-15
CA2250880C (en) 2008-01-15
AU722109C (en) 2001-07-19
NZ337109A (en) 2004-12-24
DE69738170T2 (de) 2008-01-24
DE69738170D1 (de) 2007-11-08
JP3765039B2 (ja) 2006-04-12
EP0914043A1 (en) 1999-05-12
JP4480152B2 (ja) 2010-06-16
CN1215309A (zh) 1999-04-28
ATE374034T1 (de) 2007-10-15
CN1119080C (zh) 2003-08-27
CN1495253A (zh) 2004-05-12
AU722109B2 (en) 2000-07-20
NO984627D0 (no) 1998-10-02
PT914043E (pt) 2004-02-27
FI120332B (fi) 2009-09-30
NZ331960A (en) 1999-10-28
EP0914043B1 (en) 2003-10-01
ES2206696T3 (es) 2004-05-16
DK0914043T3 (da) 2004-02-09
DE69725317T2 (de) 2004-07-29
ES2290390T3 (es) 2008-02-16
EP1382346B1 (en) 2007-09-26
CN1296477C (zh) 2007-01-24
HK1066026A1 (en) 2005-03-11
NO320334B1 (no) 2005-11-21
DE69725317D1 (de) 2003-11-06
FI981957L (fi) 1998-12-02
EP1382346A1 (en) 2004-01-21
EP0914043A4 (en) 2001-08-29
FI981957A0 (fi) 1998-09-11
HK1019037A1 (en) 2000-01-21
AU2218897A (en) 1997-10-22
JP2001503380A (ja) 2001-03-13
WO1997036495A1 (en) 1997-10-09
IL126442A0 (en) 1999-08-17
DK1382346T3 (da) 2008-01-28

Similar Documents

Publication Publication Date Title
NO984627L (no) Implanterbare, agarose-kollagenperler inneholdende celler som produserer et diffuserbart biologisk produkt og anvendelser derav
NO982722D0 (no) Absorbenter for fosfat fra et vanndig medium, samt fremstilling og anvendelse av absorbenten
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
DE69623300D1 (de) 2,4 pentadiensaurederivate mit retinoidartigen biologischen aktivität
DE69633135D1 (de) Fluorierte oniumsatze, härtbare zusammensetzungen, welche selbige enthalten, und härtungsverfahren unter deren verwendung
WO1989003846A3 (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
WO2000004865A3 (en) Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
ATE268385T1 (de) Mykrobakterielle proteine, mikroorganismen welche diese produzieren und ihre verwendung als impfstoff und zum nachweis von zuberkulose
DE3481035D1 (de) Ibuprofen, flurbiprofen und deren therapeutische verwendung.
PT946873E (pt) Metodos para diagnostico da aspergilose broncopulmonar alergica
ATE367819T1 (de) Isolierte stromazellen und methoden zu deren verwendung
CA2185112A1 (en) Humanized monoclonal antibodies against human interleukin-4
FI960369L (fi) Emässubstituoituja bentsoyyliguanidiinejä, menetelmä niiden valmistamiseksi, niiden käyttö lääkeaineena tai diagnostisena aineena sekä niitä sisältävänä lääkkeenä
AU1828388A (en) Promoters for the expression of foreign dna in methylotrophic bacteria, the obtaining thereof and the use thereof
DE69530577D1 (de) Mikrobiologische kulturflaschen, ihre herstelling und verwendung
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
EP0112299A3 (en) Method for superoxidic-dismutasis purification via chromatography by affinity
NO972221L (no) Fremgangsmåte for spyttanalyse
AU3845395A (en) Antibodies against allogenic and xenogenic proteins, their use in diagnosis and therapy and methods for the determination thereof
DK0804098T3 (da) Filter til tobaksrøg
AU528857B2 (en) Desulfurization, hydrocracking or isomerisation of hydrocarbons
ATE74968T1 (de) Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens.
FI905060A7 (fi) Menetelmä sellaisten liposomien ja/tai biologisten solujen valmistamis eksi, joihin on absorboitunut aineita, sekä niiden käyttö
BR8004879A (pt) Sistema de suspensao para cadeiras, poltronas e congeneres
IT8803542A0 (it) Procedimento per la trasformazione dei rifiuti particolarmente rifiuti urbani in sostanze utilizzabili

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees